Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569189 | 0.94 | RXFP1 (0.39) | RXFP1TDP1 | |
| SCHEMBL568927 | 0.93 | RXFP1 (0.40) | RXFP1TDP1 | |
| SCHEMBL569374 | 0.91 | RXFP1 (0.41) | RXFP1TDP1 | |
| SCHEMBL569750 | 0.90 | RXFP1 (0.41) | RXFP1TDP1 | |
| SCHEMBL569857 | 0.90 | RXFP1 (0.36) | RXFP1TDP1 | |
| SCHEMBL568935 | 0.89 | RXFP1 (0.36) | RXFP1TDP1 | |
| SCHEMBL569808 | 0.89 | RXFP1 (0.38) | RXFP1TDP1 | |
| SCHEMBL570090 | 0.88 | RXFP1 (0.38) | RXFP1TDP1 | |
| SCHEMBL568908 | 0.88 | RXFP1 (0.36) | RXFP1TDP1 | |
| SCHEMBL570335 | 0.88 | RXFP1 (0.37) | RXFP1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601190-B1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-2601190-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | AH USA 42 LLC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-8415310-B2 | Isoxazoline derivatives as antiparasitic agents | AH USA 42 LLC (US) | 2013-04-09 | — | — | US | disclosed |
| WO-2012017359-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | PFIZER INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ZOETIS SERVICES LLC | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035122-A1 | ISOXAZOLINE DERIVATIVES AS ANTIPARASITIC AGENTS | ADORA1, CYP3A7, RDX | RXFP1 26/4885TDP1 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.